Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature

Ther Deliv. 2017 Aug;8(9):737-746. doi: 10.4155/tde-2017-0058. Epub 2017 Jun 29.


Psoriasis is a common chronic immune-mediated skin disease which has a significant impact on patients' quality of life, and is associated with numerous comorbidities (i.e., psoriatic arthritis, Crohn's disease and cardiovascular disease). A greater understanding of its immunopathogenesis has guided the development of novel, more targeted therapies. Nonetheless, traditional treatment with topical agents, phototherapy and systemic medications is used in the management of the majority of psoriasis patients. Mainstay topical treatments include corticosteroids and vitamin D derivatives. Calcipotriene/betamethasone dipropionate aerosol foam is a novel single product combination, which seeks to provide superior therapeutic efficacy in addition to enhanced cosmetic properties. This article reviews the literature on the pharmacology and clinical data in terms of safety, efficacy and patient satisfaction of this topical medication.

Keywords: Enstilar®; aerosol foam; calcipotriene/betamethasone dipropionate; corticosteroids; psoriasis; topical therapies; vitamin D derivatives.

Publication types

  • Review

MeSH terms

  • Betamethasone / administration & dosage
  • Betamethasone / analogs & derivatives*
  • Betamethasone / therapeutic use
  • Calcitriol / administration & dosage
  • Calcitriol / analogs & derivatives*
  • Calcitriol / therapeutic use
  • Dermatologic Agents / administration & dosage*
  • Dermatologic Agents / therapeutic use
  • Drug Combinations
  • Humans
  • Psoriasis / drug therapy*
  • Quality of Life


  • Dermatologic Agents
  • Drug Combinations
  • calcipotriene
  • betamethasone-17,21-dipropionate
  • Betamethasone
  • Calcitriol